New Partnerships Added to World Federation of Hemophilia Twinning Program
April 17 2009 - 9:00AM
PR Newswire (US)
Wyeth and Advocacy Community Mark Continued Commitment to Patient
Care on World Hemophilia Day COLLEGEVILLE, Pa., April 17
/PRNewswire/ -- In honor of the twentieth Anniversary of World
Hemophilia Day, Wyeth Pharmaceuticals, a division of Wyeth
(NYSE:WYE), together with the World Federation of Hemophilia (WFH),
announce the addition of five new partnerships to the WFH Twinning
Program. Begun in 1994, the Twinning Program aims to increase the
level of diagnosis and care for people with hemophilia by pairing
emerging treatment centers and patient organizations with more
established centers and organizations around the world. Wyeth has
been the sole corporate sponsor of the program since 2001, which
now includes a total of 31 partnerships worldwide. "Wyeth
recognizes that effective collaboration between advocacy
organizations and industry can help people with chronic illnesses
such as hemophilia," says Angela Rossetti, Assistant Vice
President, and Global Business Manager for Wyeth Hemophilia. "Our
continued support of the Twinning Program -- now in its 16th year
-- and other advocacy initiatives is part of a global collaborative
effort designed to help patients with hemophilia and their families
receive access to better care." The new Twinning partnerships
include the following Hemophilia Treatment Center Twins: Addis
Ababa (Ethiopia) and Chapel Hill (North Carolina, USA); Dakar
(Senegal) and Paris (France); Quito (Ecuador) and Caracas
(Venezuela); Manipal (India) and Albuquerque, (New Mexico, USA);
Skopje (Macedonia) and Bonn (Germany). For more information on the
Twinning Program and to view a video of the Lima (Peru) and Fort
Worth (Texas, USA) Twin in action, visit http://www.wfh.org/.
"World Hemophilia Day is an opportunity for all of us in the
bleeding disorders community to celebrate our achievements and
raise awareness," said Mark Skinner, WFH president. "The theme of
this year's World Hemophilia Day, 'Together, we care' embodies our
spirit of collaboration to work together to improve care for people
with bleeding disorders. We are grateful to Wyeth for its support
of our programs, especially the Twinning Program, which play a key
role in achieving our vision of Treatment for All." THE HEMOPHILIA
COMMUNITY AND WYETH: A HISTORY OF PARTNERSHIP Support of Children's
Camping Initiatives For years, Wyeth has recognized the importance
of the summer camp experience to children in the bleeding disorders
community. Since 1998, Wyeth has been a major sponsor of
Barretstown in Ireland -- an innovative recreational facility --
where children with serious illnesses, including children with
hemophilia, can participate in a range of fun activities that also
are designed to promote self-confidence, independence, trust and
coping skills. In addition to its ongoing support, Wyeth works with
Barretstown to help run special camps for children with hemophilia.
Wyeth is also the founding and exclusive sponsor of NACCHO (North
American Camping Conference of Hemophilia Organizations). The
annual NACCHO conference is dedicated to the sharing of best
practices for bleeding disorder summer camps. Through NACCHO,
children attending summer camp also have the opportunity to
participate in Leading Edge: Exploring the Outer Limits, a
nationally run adventure program that focuses on self-confidence
development for youth and adolescents in the bleeding disorders
community. Through its grants to NACCHO, Wyeth has supported 1,000
campers nationally, and 500 campers internationally.
Wyeth-Sponsored Support Programs Education and access to care are
critical to the health and well-being of patients with hemophilia.
In addition to other initiatives that support the bleeding
disorders community, Wyeth proudly awards scholarships to deserving
students who have hemophilia. For the 2008-2009 academic year
alone, Wyeth awarded up to $100,000 to students with bleeding
disorders seeking collegiate, graduate and vocational degrees.
Wyeth also works to help patients with hemophilia maintain access
to hemophilia therapy. Through its Factor Resource Program, Wyeth
provides services designed to assist patients experiencing
financial hardship or treatment access issues, including the
Insurance-Coverage Program and the Patient Assistance Program.
Individuals can get more information about these programs through
the Wyeth Hemophilia Hotline (1-888-999-2349). Assisting Advocacy
Organizations Wyeth also provides assistance to numerous advocacy
organizations and their initiatives, including: -- WFH's Global
Alliance for Progress (GAP) program, a 10-year healthcare
development initiative to facilitate earlier and accurate diagnosis
and treatment of people with hemophilia and other bleeding
disorders in developing countries. -- National Hemophilia
Foundation's Campaign for Our Future, a program designed to provide
access to care for all members of the bleeding disorders community.
-- Hemophilia Federation of America's Helping Hands program, which
provides emergency financial assistance for members of the bleeding
disorders community. Last year, Wyeth supported 122 families
through its grants to the Hemophilia Federation of America. --
Coalition for Hemophilia B, an organization that provides
information about treatment that will improve the quality of life
of patients with hemophilia B. -- International Society for
Thrombosis and Haemostasis, which fosters and advances science
relating to the important medical problems of thrombosis and
abnormalities of haemostasis and vascular biology. Wyeth and
Hemophilia Wyeth works to help improve the health of hemophilia
patients through education, patient assistance programs and by
supporting associations throughout the world. For more information
on Wyeth and hemophilia, visit http://www.hemophiliavillage.com/, a
comprehensive site that serves as a resource for patients, parents,
and caregivers in the hemophilia community. About Wyeth
Pharmaceuticals Wyeth Pharmaceuticals, a division of Wyeth, has
leading products in the areas of women's health care, infectious
disease, gastrointestinal health, central nervous system,
inflammation, transplantation, hemophilia, oncology, vaccines and
nutritional products. Wyeth is one of the world's largest
research-driven pharmaceutical and health care products companies.
It is a leader in the discovery, development, manufacturing and
marketing of pharmaceuticals, vaccines, biotechnology products,
nutritionals and non-prescription medicines that improve the
quality of life for people worldwide. The Company's major divisions
include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health. The statements in this press release that are
not historical facts are forward-looking statements that are
subject to risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, among others,
risks related to our proposed merger with Pfizer, including
satisfaction of the conditions of the proposed merger on the
proposed timeframe or at all, contractual restrictions on the
conduct of our business included in the merger agreement, and the
potential for loss of key personnel, disruption in key business
activities or any impact on our relationships with third parties as
a result of the announcement of the proposed merger; the inherent
uncertainty of the timing and success of, and expense associated
with, research, development, regulatory approval and
commercialization of our products and pipeline products; government
cost-containment initiatives; restrictions on third-party payments
for our products; substantial competition in our industry,
including from branded and generic products; emerging data on our
products and pipeline products; the importance of strong
performance from our principal products and our anticipated new
product introductions; the highly regulated nature of our business;
product liability, intellectual property and other litigation risks
and environmental liabilities; the outcome of government
investigations; uncertainty regarding our intellectual property
rights and those of others; difficulties associated with, and
regulatory compliance with respect to, manufacturing of our
products; risks associated with our strategic relationships; global
economic conditions; interest and currency exchange rate
fluctuations and volatility in the credit and financial markets;
changes in generally accepted accounting principles; trade buying
patterns; the impact of legislation and regulatory compliance;
risks and uncertainties associated with global operations and
sales; and other risks and uncertainties, including those detailed
from time to time in our periodic reports filed with the Securities
and Exchange Commission, including our current reports on Form 8-K,
quarterly reports on Form 10-Q and annual report on Form 10-K,
particularly the discussion under the caption "Item 1A, Risk
Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2008, which was filed with the Securities and Exchange
Commission on February 27, 2009. The forward-looking statements in
this press release are qualified by these risk factors. We assume
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise. DATASOURCE: Wyeth Pharmaceuticals CONTACT: Media,
Danielle Halstrom, Wyeth Pharmaceuticals, +1-484-865-2020, or
Douglas Petkus, Wyeth, +1-973-660-5218, or Investors, Justin
Victoria, Wyeth, +1-973-660-5340 Web Site: http://www.wyeth.com/
Copyright
Wyeth (NYSE:WYE)
Historical Stock Chart
From May 2024 to Jun 2024
Wyeth (NYSE:WYE)
Historical Stock Chart
From Jun 2023 to Jun 2024